Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Change In Receivables : ¥0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Wuhan Easy Diagnosis Biomedicine Co Change In Receivables?

Wuhan Easy Diagnosis Biomedicine Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0.0 Mil. It means Wuhan Easy Diagnosis Biomedicine Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Wuhan Easy Diagnosis Biomedicine Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥1,255.6 Mil. It means Wuhan Easy Diagnosis Biomedicine Co's Accounts Receivable declined by ¥1,255.6 Mil from Dec. 2022 to Dec. 2023 .

Wuhan Easy Diagnosis Biomedicine Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥1,064.2 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Wuhan Easy Diagnosis Biomedicine Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 1,592.93.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Wuhan Easy Diagnosis Biomedicine Co's liquidation value for the three months ended in Mar. 2024 was ¥1,036.4 Mil.

Wuhan Easy Diagnosis Biomedicine Co Change In Receivables Historical Data

The historical data trend for Wuhan Easy Diagnosis Biomedicine Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Easy Diagnosis Biomedicine Co Change In Receivables Chart

Wuhan Easy Diagnosis Biomedicine Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-4.12

-320.05

-722.32

-2,324.76

1,255.65

Wuhan Easy Diagnosis Biomedicine Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Wuhan Easy Diagnosis Biomedicine Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.0 Mil.

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Wuhan Easy Diagnosis Biomedicine Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1064.22	/	60.963	*	91
=	1,592.93

2. In Ben Graham's calculation of liquidation value, Wuhan Easy Diagnosis Biomedicine Co's accounts receivable are only considered to be worth 75% of book value:

Wuhan Easy Diagnosis Biomedicine Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1108.462	-	932.938	+	0.75 * 1064.22	+	0.5 * 125.428
=	1,036.4

Wuhan Easy Diagnosis Biomedicine Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Wuhan Easy Diagnosis Biomedicine Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Wuhan Easy Diagnosis Biomedicine Co Ltd (SZSE:002932) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1 Dongxin Road, 2 Floor, Building E, International Students Pioneer Park, Guandong Science and Technology Park, Donghu Development Zone, Hubei, Wuhan, CHN, 430075

Website

http://www.mdeasydiagnosis.com

Wuhan Easy Diagnosis Biomedicine Co Ltd is engaged in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments and mobile ECG products. The company's product profile consists of Molecular diagnosis, Chemiluminescence, Blood gas analysis, and others. It also provides various other solutions such as Mingde Biomolecular Diagnostic Service Solution, Mingde Biothoracic Center Solution, POCT Solution, Remote ECG network construction solution, and others.

Executives

Wang Rui	Directors, executives
Wang Jian Fei	Director

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Headlines

No Headlines